Emerging Paradigms for Small Molecules-Based Therapies Targeting P53 in multiple myeloma

Multiple Myeloma (MM) is a plasma cell malignancy characterized by the accumulation of malignant plasma cells in the bone marrow [1]. Despite recent advances in the introduction of the new drugs MM is still an incurable disease for its resistance to current therapies [1, 2]. Understanding the mechanisms of programmed cell death or apoptosis is essential for the development of novel interventions to improve the survival of cancer patients. p53, a tumor suppressor protein with its ability to induce apoptosis and being central to pro-apoptotic signalling in cancer therapy, has been used as a target for cancer therapy for the past two decades. p53 senses various stress signals and upon activation p53 coordinates a diverse cellular stress response.